< Back to latest news & events

Event

Seminar: Strategies and updates on patenting inventions relating to personalised medicine in Europe and the US – Basel

October 2019

Event date: 17th October 2019

HGF is hosting a seminar in Der Teufelhof Basel on Thursday 17th October at 6pm. Partner Dr Leena Contarino and Patent Director Dr Laurence Gainey will consider strategies for patenting inventions in Europe and the US.

Targeted intervention (also known as personalised medicine or precision medicine) is a rapidly evolving field of medicine in which treatments are selected based on the detection of disease markers in individual patients. This enables doctors to prescribe treatment regimens that are tailored to individual patients’ medical needs.

Targeted intervention is already well established modern oncology where new drugs are now often approved together with companion diagnostics used to identify particular markers or genetic mutations in a patient. It is likely that targeted intervention will also become a feature in other therapy areas as the technology evolves. Patenting and enforcing patents covering personalised medicine inventions can be challenging, most notably in the USA.

This seminar will consider strategies for patenting these inventions in Europe and the US, including an update on the evolving situation in the US such as: legislative efforts, USPTO updated guidance and recent court cases such as Athena Diagnostics, Inc. v. Mayo Collaborative Services, LLC (Fed. Cir. July 3, 2019).

To register please email [email protected].

Latest updates

HGF Ranked #1 in the UK for Trade Mark Portfolios in the 2025 Trade Mark Filing Trends Report by Clarivate.

HGF has achieved the #1 ranking for the UK for trade mark portfolios in the newly released 2025 Trade mark Filing Trends report by Clarivate, recognising the firm as a …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

The Enlarged Board of Appeal has today issued its decision in seminal case G1/24.

G1/24, described as one of the most important cases in decades, relates to how claims of patents are to be interpreted by the Boards of Appeal and, by extension, all …

Read article

UPC’s Hamburg Local Division provides guidance on the extent to which a patent may be used as its own “lexicon”

Agfa NV v Gucci & Anors. [UPC_CFI_278/2023] – Hamburg Local Division of the UPC (Klepsch, Schilling, Sarlin) – 30 April 2025 While we await a decision on G1/24 from the …

Read article

MevoCem Nominated for the Earthshot Prize by CIPA

We’re delighted to share that our client, Material Evolution, has been nominated by the Chartered Institute of Patent Attorneys (CIPA) for the globally renowned Earthshot Prize, in recognition of their …

Read article

Agritech Thymes: Agritech 2030: Forecasting the Technologies Poised to Transform Farming

Whilst yet to recover to the levels of 2011-2021, where capital invested in agritech increased 20-fold, investor funding in agritech is starting to pick up, and 2025 is set to …

Read article

UPC delivers first judgment on Validity and Infringement of a Second Medical Use Claim

Sanofi Biotechnology SAS & Anor v Amgen, Inc., & Ors– Thomas, Thom, Kupecz and Dorland-Galliot – [UPC_CFI_505/2024] The Dusseldorf Local Division (LD) has delivered the UPC’s first Judgment on second …

Read article